ZLDPF
Zealand Pharma A/S/ADR
$50.26
+2.80%
No data for this timeframe.
Vol
Recent Activity
May 18, 2026
clinical_trial_readout
T-90d Trial Readout: Petrelintide (Phase 2)
Trial: Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Dia
Analyst Ratings
6Strong Buy
12Buy
6Hold
1Sell
0Strong Sell
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 72% buy across 25 analysts — 6 strong buy, 12 buy, 6 hold, 1 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $2.4B | -73.6% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $1.3B | 2522.7% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $4.5B | -51.3% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $4.3B | -3.9% | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 6 | 12 | 6 | 1 | 0 | 72% | |
| Apr 1, 2026 | 6 | 12 | 6 | 1 | 0 | 72% | |
| Mar 1, 2026 | 7 | 13 | 3 | 1 | 0 | 83% | |
| Feb 1, 2026 | 7 | 13 | 3 | 1 | 0 | 83% | |
| Jan 1, 2026 | 7 | 13 | 3 | 1 | 0 | 83% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 18, 2026
Clinical Trial
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
Phase Phase 2 — ACTIVE_NOT_RECRUITING
May 18, 2026
clinical_trial_readout
T-90d Trial Readout: Petrelintide (Phase 2)
Trial: Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
Sponsor: Zealand Pharma
Phase: P
May 15, 2026
clinical_trial_readout
T-90d Trial Readout: Petrelintide (Phase 2)
Trial: Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
Sponsor: Zealand Pharma
Phase: P
Apr 1, 2026
Clinical Trial
Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities
Phase Phase 2 — COMPLETED